South San Francisco biotech powerhouse Genentech is buying into a preclinical cancer-fighting program from Forma Therapeutics of Cambridge, Mass. As it turns out, Genentech’s partnering chief, James Sabry, is on my talk-to list today, the first day of the Biotechnology Industry Organization convention in Washington, D.C.
No comments:
Post a Comment